The most frequent mutations of CM, such as BRAF, N-Ras, K-Ras, H-Ras, and NF1, alterations of TERT-promoter or tumor suppressor genes such as ARID2, TP53, PTEN and also CDKN2A (8), have been rarely found in UM and most therapeutic strategies used in CM have proved ineffective in metastatic UM (3). This evidence concerns the gene ARID2 and cutaneous mastocytosis.